Quidel Corp (QDEL) Tops Q2 EPS by 12c, Slight Beat on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Quidel Reports Second Quarter 2018 Financial Results
August 7, 2018 4:10 PM EDTSAN DIEGO--(BUSINESS WIRE)-- Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the second quarter ended June 30, 2018.
Second Quarter 2018 Highlights
Total revenue was $103.2 million as compared to $38.3 million in the second quarter of 2017. Cardiac Immunoassay revenue was $69.9 million. Influenza revenue was $5.5 million as compared to $10.1 million in the second quarter of 2017. Reduced debt by an additional $98.6 million through convertible note... More